Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director · CEO & President | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,278 |
Ending reported balance
After 2026-02-27 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2026-02-27 · Sale · Disposed 400 · Balance 137,878 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3: Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76). Row 2 · 2026-02-27 · Sale · Disposed 120 · Balance 137,758 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51). Row 3 · 2026-02-27 · Sale · Disposed 240 · Balance 137,518 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85). Row 4 · 2026-02-27 · Sale · Disposed 2,510 · Balance 135,008 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55). Row 5 · 2026-02-27 · Sale · Disposed 3,278 · Balance 131,730 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7: Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56). Row 6 · 2026-02-27 · Sale · Disposed 460 · Balance 131,270 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8: Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79). Row 7 · 2026-02-27 · Sale · Disposed 2,725 · Balance 128,545 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9: Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01). Row 8 · 2026-02-27 · Sale · Disposed 949 · Balance 127,596 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10: Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85). Row 9 · 2026-02-27 · Sale · Disposed 2,520 · Balance 125,076 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11: Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77). Row 10 · 2026-02-27 · Sale · Disposed 3,498 · Balance 121,578 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12: Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75). Row 11 · 2026-02-27 · Sale · Disposed 15,580 · Balance 105,998 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F13: Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78). Row 12 · 2026-02-27 · Sale · Disposed 5,995 · Balance 100,003 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F14: Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74). Row 13 · 2026-02-27 · Sale · Disposed 1,725 · Balance 98,278 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F15: Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17). |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025.
F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3: Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76).
F4: Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51).
F5: Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85).
F6: Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55).
F7: Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56).
F8: Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79).
F9: Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01).
F10: Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85).
F11: Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77).
F12: Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75).
F13: Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78).
F14: Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74).
F15: Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ginkgo Bioworks Holdings, Inc.
Report date June 12, 2024 · Filed June 14, 2024
Section 16 reporting ended · disclosed 2024-06-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 186,002 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Exercise / conversion · Acquired 105,263 · Balance 186,002 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-12 · Exercise / conversion · Disposed 105,263 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2023 Filed Dec 15, 2023 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,098 | $397.00 | $2,023,906.00 |
DisclosureSEC source: 0000875320-23-000058 · wk-form4_1702675367.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,711 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,097 | $377.00 | $1,921,569.00 |
DisclosureSEC source: 0000875320-23-000035 · wk-form4_1700082955.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,809 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023. Read SEC document |
| July 17, 2023 Filed Jul 18, 2023 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,828 | $355.00 | $2,778,940.00 |
DisclosureSEC source: 0001209191-23-042557 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,906 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 17:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantStock Option · Derivative | 139,860 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001127602-23-019171 · form4.xml · derivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,860 Underlying: Class A Common Stock · 139,860 shares Expires 2033-06-16 F3 · shares: In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000. F2 · derivative.exercise_date: The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date. RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023. F3 · derivative.underlying_shares: In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 17:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 105,263 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019171 · form4.xml · derivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,263 Underlying: Class A Common Stock · 105,263 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date. RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023. F2 · derivative.expiration_date: The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date. RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023. Read SEC document |
| April 27, 2023 Filed May 1, 2023 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 38 | $340.19 | $12,927.22 |
DisclosureSEC source: 0001209191-23-026270 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,652 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022. Read SEC document |
| April 27, 2023 Filed May 1, 2023 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,668 | $339.43 | $566,169.24 |
DisclosureSEC source: 0001209191-23-026270 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,690 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $339.43 (range $339.00 to $339.98). Read SEC document |
| April 27, 2023 Filed May 1, 2023 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,611 | $338.69 | $545,629.59 |
DisclosureSEC source: 0001209191-23-026270 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,358 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $338.69 (range $338.00 to $338.99). Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 9,386 | $289.12 | $2,713,680.32 |
DisclosureSEC source: 0001209191-23-013718 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,969 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 9,359 | $292.85 | $2,740,783.15 |
DisclosureSEC source: 0001209191-23-011686 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,355 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 5,990 | $298.26 | $1,786,577.40 |
DisclosureSEC source: 0001209191-23-009198 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,714 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,372 | $294.33 | $992,480.76 |
DisclosureSEC source: 0001209191-23-009198 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,704 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 26,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006946 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,076 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 29,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006946 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,104 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006946 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,986 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,000 | $315.05 | $3,150,500.00 |
DisclosureSEC source: 0001209191-23-005219 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,598 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $315.05 (range $315.00 to $315.23). Read SEC document |
| September 30, 2022 Filed Nov 10, 2022 17:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 9,818 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035555 · doc4.xml · derivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 9,818 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Class A common stock. F1 · kind: Represents the conversion of restricted stock units ("RSUs") into Class A common stock. F3 · derivative.exercise_date: In accordance with an agreement between the Reporting Person and the issuer to delay vesting of the RSUs, the RSUs vested on September 30, 2022. F3 · derivative.expiration_date: In accordance with an agreement between the Reporting Person and the issuer to delay vesting of the RSUs, the RSUs vested on September 30, 2022. F2 · derivative.underlying_shares: Each RSU represents a contingent right to receive one share of Class A common stock. Read SEC document |
| September 30, 2022 Filed Nov 10, 2022 17:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 9,818 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035555 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock units ("RSUs") into Class A common stock. F1 · shares: Represents the conversion of restricted stock units ("RSUs") into Class A common stock. F1 · price: Represents the conversion of restricted stock units ("RSUs") into Class A common stock. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,689 | $305.06 | $3,565,846.34 |
DisclosureSEC source: 0000899243-22-029032 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,598 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $305.06 (range $305.00 to $305.22). Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,689 | $291.30 | $3,405,005.70 |
DisclosureSEC source: 0000899243-22-024385 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,153 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $291.30 (range $291.00 to $291.49). Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 21:12 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantStock Option · Derivative | 108,516 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0000899243-22-022285 · doc4.xml · derivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,516 Underlying: Class A Common Stock · 108,516 shares Expires 2032-06-10 F2 · shares: In accordance with the Non-Employee Director Compensation Policy of the Issuer, the Black-Scholes value of the option award as of the grant date is $200,000. F1 · derivative.exercise_date: The vesting date of the restricted stock units and stock options, and in the case of the stock options, the exercise date, will be the earlier of either June 10, 2023 or the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 21:12 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantClass A Common Stock | 70,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-022285 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,921 F1 · shares: The vesting date of the restricted stock units and stock options, and in the case of the stock options, the exercise date, will be the earlier of either June 10, 2023 or the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 7,246 | $227.86 | $1,651,073.56 |
DisclosureSEC source: 0000899243-22-008116 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,842 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 8,584 | $232.51 | $1,995,865.84 |
DisclosureSEC source: 0000899243-22-007208 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,088 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,031 | $237.74 | $720,589.94 |
DisclosureSEC source: 0001209191-22-009236 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,672 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 29,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006775 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,703 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 29,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006775 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,586 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 9,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006775 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,554 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 17:00 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 9,818 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045805 · doc4.xml · derivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,818 Underlying: Class A Common Stock · 9,818 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Class A common stock. F2 · derivative.exercise_date: The RSUs vest on the day immediately prior to the Issuer's next annual meeting of shareholders and have no expiration date. F2 · derivative.expiration_date: The RSUs vest on the day immediately prior to the Issuer's next annual meeting of shareholders and have no expiration date. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 21:51 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantStock Option · Derivative | 17,649 | $0.00 Strike: $11.42 | $0.00 |
DisclosureSEC source: 0000899243-21-036687 · doc4.xml · derivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,649 Underlying: Class A Common Stock · 17,649 shares Expires 2031-09-15 F2 · derivative.exercise_date: The stock option vests on the earlier of either September 16, 2022 or the day before the Issuer's next annual meeting of stockholders. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 21:51 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantStock Option · Derivative | 51,782 | $0.00 Strike: $11.42 | $0.00 |
DisclosureSEC source: 0000899243-21-036687 · doc4.xml · derivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,782 Underlying: Class A Common Stock · 51,782 shares Expires 2031-09-15 F1 · derivative.exercise_date: The stock option vests in three substantially equal annual installments beginning on September 16, 2022. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 12:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 4,243 | $196.34 | $833,070.62 |
DisclosureSEC source: 0001209191-21-052881 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,754 F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. F3 · price: Open market purchases reported on this line occurred at a weighted average price of $196.34 (range $195.74 to $196.58). Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 12:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 5,757 | $195.14 | $1,123,420.98 |
DisclosureSEC source: 0001209191-21-052881 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,511 F1 · price: Open market purchases reported on this line occurred at a weighted average price of $195.14 (range $194.63 to $195.50). F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,898 | $217.57 | $630,517.86 |
DisclosureSEC source: 0001209191-21-014723 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,643 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,080 | $211.75 | $440,440.00 |
DisclosureSEC source: 0001209191-21-012334 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,541 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,962 | $214.16 | $634,341.92 |
DisclosureSEC source: 0001209191-21-010098 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,621 Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 29,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008121 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,583 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008121 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,552 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008121 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,164 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 509 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-045935 · doc4.xml · derivative · entry 9 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,058 Underlying: Common Stock · 509 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,564 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-045935 · doc4.xml · derivative · entry 8 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,642 Underlying: Common Stock · 1,564 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 93 | $273.27 | $25,414.11 |
DisclosureSEC source: 0001209191-20-045935 · doc4.xml · nonDerivative · entry 7 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,626 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 487 | $272.76 | $132,834.12 |
DisclosureSEC source: 0001209191-20-045935 · doc4.xml · nonDerivative · entry 6 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,719 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $272.76 (range $272.25 to $272.99). Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 471 | $271.42 | $127,838.82 |
DisclosureSEC source: 0001209191-20-045935 · doc4.xml · nonDerivative · entry 5 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,206 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $271.42 (range $270.97 to $271.88). Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 870 | $270.36 | $235,213.20 |
DisclosureSEC source: 0001209191-20-045935 · doc4.xml · nonDerivative · entry 4 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,677 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $270.36 (range $269.90 to $270.85). Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 152 | $269.11 | $40,904.72 |
DisclosureSEC source: 0001209191-20-045935 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,547 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $269.11 (range $268.69 to $269.59). F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 509 | $155.57 | $79,185.13 |
DisclosureSEC source: 0001209191-20-045935 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,564 | $187.53 | $293,296.92 |
DisclosureSEC source: 0001209191-20-045935 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9 | $288.37 | $2,595.33 |
DisclosureSEC source: 0001209191-20-030498 · doc4.xml · nonDerivative · entry 10 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,626 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $288.37 (range $288.23 to $288.47). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 19 | $287.63 | $5,464.97 |
DisclosureSEC source: 0001209191-20-030498 · doc4.xml · nonDerivative · entry 9 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,635 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $287.63 (range $287.18 to $288.10). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.